topic excipients 
Pharmaceutical Technology
MAY 26, 2023
Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. Topic sponsors are not involved in the creation of editorial content.
European Pharmaceutical Review
MARCH 10, 2023
Currently, effective topical administration is challenging as the industry aims to prolong drug residence time and guarantee appropriate ocular permeation. How to enhance ocular drug bioavailability One approach to enhance drug bioavailability after topical administration is increasing corneal permeability.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 9, 2023
VEVYE, the development name of which is CyclASol, is a cyclosporine, solubilised solution in a new, water-free excipient. CyclASol is topical anti-inflammatory and immunomodulating ophthalmic drug solution containing 0.1%
Pharmaceutical Technology
APRIL 20, 2023
In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.
Pharmaceutical Technology
JUNE 10, 2023
It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.
Pharmaceutical Technology
JUNE 10, 2023
It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.
European Pharmaceutical Review
JANUARY 29, 2024
Conclusions Of the five major topics covered during 2023, it is likely that all will feature to a greater or lesser extent during 2024. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility. Lessons learnt from presence of N-nitrosamine impurities in sartan medicines.
Expert insights. Personalized for you.
105 
Let's personalize your content